Search

Your search keyword '"Mercado, Noe B."' showing total 162 results
Start Over Author "Mercado, Noe B."
162 results on '"Mercado, Noe B."'

2. Long-acting capsid inhibitor protects macaques from repeat SHIV challenges

Author

Vidal, Samuel J., Bekerman, Elena, Hansen, Derek, Lu, Bing, Wang, Kelly, Mwangi, Judy, Rowe, William, Campigotto, Federico, Zheng, Jim, Kato, Darryl, Chandrashekar, Abishek, Barrett, Julia, Patel, Shivani, Wan, Huahua, Anioke, Tochi, Mercado, Noe B., Nkolola, Joseph P., Ferguson, Melissa J., Rinaldi, William J., Callebaut, Christian, Blair, Wade, Cihlar, Tomas, Geleziunas, Romas, Yant, Stephen R., and Barouch, Dan H.

Published
2022
Full Text
View/download PDF

3. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

Author

Gebre, Makda S., Rauch, Susanne, Roth, Nicole, Yu, Jingyou, Chandrashekar, Abishek, Mercado, Noe B., He, Xuan, Liu, Jinyan, McMahan, Katherine, Martinot, Amanda, Martinez, David R., Giffin, Victoria, Hope, David, Patel, Shivani, Sellers, Daniel, Sanborn, Owen, Barrett, Julia, Liu, Xiaowen, Cole, Andrew C., Pessaint, Laurent, Valentin, Daniel, Flinchbaugh, Zack, Yalley-Ogunro, Jake, Muench, Jeanne, Brown, Renita, Cook, Anthony, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Boon, Adrianus C. M., Baric, Ralph S., Mueller, Stefan O., Petsch, Benjamin, and Barouch, Dan H.

Published
2022
Full Text
View/download PDF

4. Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques

Author

Ventura, John D., Nkolola, Joseph P., Chandrashekar, Abishek, Borducchi, Erica N., Liu, Jinyan, Mercado, Noe B., Hope, David L., Giffin, Victoria M., McMahan, Katherine, Geleziunas, Romas, Murry, Jeffrey P., Yang, Yunling, Lewis, Mark G., Pau, Maria G., Wegmann, Frank, Schuitemaker, Hanneke, Fray, Emily J., Kumar, Mithra R., Siliciano, Janet D., Siliciano, Robert F., Robb, Merlin L., Michael, Nelson L., and Barouch, Dan H.

Published
2022
Full Text
View/download PDF

5. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques

Author

Walker-Sperling, Victoria E. K., Mercado, Noe B., Chandrashekar, Abishek, Borducchi, Erica N., Liu, Jinyan, Nkolola, Joseph P., Lewis, Mark, Murry, Jeffrey P., Yang, Yunling, Geleziunas, Romas, Robb, Merlin L., Michael, Nelson L., Pau, Maria G., Wegmann, Frank, Schuitemaker, Hanneke, Fray, Emily J., Kumar, Mithra R., Siliciano, Janet D., Siliciano, Robert F., and Barouch, Dan H.

Published
2022
Full Text
View/download PDF

6. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques

Author

He, Xuan, Chandrashekar, Abishek, Zahn, Roland, Wegmann, Frank, Yu, Jingyou, Mercado, Noe B., McMahan, Katherine, Martinot, Amanda J., Piedra-Mora, Cesar, Beecy, Sidney, Ducat, Sarah, Chamanza, Ronnie, Huber, Sietske Rosendahl, van Heerden, Marjolein, van der Fits, Leslie, Borducchi, Erica N., Lifton, Michelle, Liu, Jinyan, Nampanya, Felix, Patel, Shivani, Peter, Lauren, Tostanoski, Lisa H., Pessaint, Laurent, Van Ry, Alex, Finneyfrock, Brad, Velasco, Jason, Teow, Elyse, Brown, Renita, Cook, Anthony, Andersen, Hanne, Lewis, Mark G., Schuitemaker, Hanneke, and Barouch, Dan H.

Published
2021
Full Text
View/download PDF

7. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques

Author

Yu, Jingyou, Tostanoski, Lisa H., Mercado, Noe B., McMahan, Katherine, Liu, Jinyan, Jacob-Dolan, Catherine, and Chandrashekar, Abishek

Subjects
Janssen COVID-19 Vaccine (Vaccine) -- Testing -- Physiological aspects, Control, Testing, Prevention, Physiological aspects, Models, SARS-CoV-2 variants -- Control, COVID-19 vaccines -- Physiological aspects -- Testing, COVID-19 -- Prevention -- Models
Abstract

Author(s): Jingyou Yu [sup.1] , Lisa H. Tostanoski [sup.1] , Noe B. Mercado [sup.1] , Katherine McMahan [sup.1] , Jinyan Liu [sup.1] , Catherine Jacob-Dolan [sup.1] [sup.2] , Abishek Chandrashekar [...], The emergence of SARS-CoV-2 variants that partially evade neutralizing antibodies poses a threat to the efficacy of current COVID-19 vaccines.sup.1,2. The Ad26.COV2.S vaccine expresses a stabilized spike protein from the WA1/2020 strain of SARS-CoV-2, and has recently demonstrated protective efficacy against symptomatic COVID-19 in humans in several geographical regions--including in South Africa, where 95% of sequenced viruses in cases of COVID-19 were the B.1.351 variant.sup.3. Here we show that Ad26.COV2.S elicits humoral and cellular immune responses that cross-react with the B.1.351 variant and protects against B.1.351 challenge in rhesus macaques. Ad26.COV2.S induced lower binding and neutralizing antibodies against B.1.351 as compared to WA1/2020, but elicited comparable CD8 and CD4 T cell responses against the WA1/2020, B.1.351, B.1.1.7, P.1 and CAL.20C variants. B.1.351 infection of control rhesus macaques resulted in higher levels of virus replication in bronchoalveolar lavage and nasal swabs than did WA1/2020 infection. Ad26.COV2.S provided robust protection against both WA1/2020 and B.1.351, although we observed higher levels of virus in vaccinated macaques after B.1.351 challenge. These data demonstrate that Ad26.COV2.S provided robust protection against B.1.351 challenge in rhesus macaques. Our findings have important implications for vaccine control of SARS-CoV-2 variants of concern. SARS-CoV-2 challenge of rhesus macaques demonstrates that the Ad26.COV2.S vaccine induces robust protection against both the WA1/2020 isolate and the B.1.351 variant of concern.

Published
2021
Full Text
View/download PDF

8. Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques

Author

Alter, Galit, Yu, Wen-Han, Chandrashekar, Abishek, Borducchi, Erica N., Ghneim, Khader, Sharma, Ashish, Nedellec, Rebecca, McKenney, Katherine R., Linde, Caitlyn, Broge, Thomas, Suscovich, Todd J., Linnekin, Tom, Abbink, Peter, Mercado, Noe B., Nkolola, Joseph P., McMahan, Katherine, Bondzie, Esther A., Hamza, Venous, Peter, Lauren, Kordana, Nicole, Mahrokhian, Shant, Seaman, Michael S., Li, Wenjun, Lewis, Mark G., Lauffenburger, Douglas A., Hangartner, Lars, Sekaly, Rafick-Pierre, and Barouch, Dan H.

Published
2020
Full Text
View/download PDF

10. Correlates of protection against SARS-CoV-2 in rhesus macaques

Author

McMahan, Katherine, Yu, Jingyou, Mercado, Noe B., Loos, Carolin, Tostanoski, Lisa H., Chandrashekar, Abishek, and Liu, Jinyan

Subjects
Prevention, Analysis, Dosage and administration, Methods, COVID-19 vaccines -- Dosage and administration, Vaccination -- Methods, Immune response -- Analysis, COVID-19 -- Prevention
Abstract

Author(s): Katherine McMahan [sup.1] , Jingyou Yu [sup.1] , Noe B. Mercado [sup.1] , Carolin Loos [sup.2] [sup.3] , Lisa H. Tostanoski [sup.1] , Abishek Chandrashekar [sup.1] , Jinyan Liu [...], Recent studies have reported the protective efficacy of both natural.sup.1 and vaccine-induced.sup.2-7 immunity against challenge with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques. However, the importance of humoral and cellular immunity for protection against infection with SARS-CoV-2 remains to be determined. Here we show that the adoptive transfer of purified IgG from convalescent rhesus macaques (Macaca mulatta) protects naive recipient macaques against challenge with SARS-CoV-2 in a dose-dependent fashion. Depletion of CD8.sup.+ T cells in convalescent macaques partially abrogated the protective efficacy of natural immunity against rechallenge with SARS-CoV-2, which suggests a role for cellular immunity in the context of waning or subprotective antibody titres. These data demonstrate that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune responses may contribute to protection if antibody responses are suboptimal. We also show that higher antibody titres are required for treatment of SARS-CoV-2 infection in macaques. These findings have implications for the development of SARS-CoV-2 vaccines and immune-based therapeutic agents. Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2.

Published
2021
Full Text
View/download PDF

11. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Author

Tostanoski, Lisa H., Wegmann, Frank, Martinot, Amanda J., Loos, Carolin, McMahan, Katherine, Mercado, Noe B., and Yu, Jingyou

Subjects
Testing, Care and treatment, COVID-19 vaccines -- Testing, COVID-19 -- Care and treatment
Abstract

Author(s): Lisa H. Tostanoski [sup.1] , Frank Wegmann [sup.2] , Amanda J. Martinot [sup.1] [sup.3] , Carolin Loos [sup.4] [sup.5] , Katherine McMahan [sup.1] , Noe B. Mercado [sup.1] , [...], Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death.sup.1-4. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters.sup.5-7 and nonhuman primates.sup.8-10 have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates.sup.11-13. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis. A single immunization with an adenovirus vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein induces protection against SARS-CoV-2-induced weight loss, pneumonia and mortality in hamsters.

Published
2020
Full Text
View/download PDF

12. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Author

Mercado, Noe B., Zahn, Roland, Wegmann, Frank, Loos, Carolin, Chandrashekar, Abishek, Yu, Jingyou, and Liu, Jinyan

Subjects
Janssen COVID-19 Vaccine (Vaccine) -- Dosage and administration -- Testing, Testing, Dosage and administration, Methods, Health aspects, Outcome and process assessment (Medical care) -- Methods, Rhesus monkey -- Testing -- Health aspects, COVID-19 vaccines -- Testing -- Dosage and administration, Outcome and process assessment (Health Care) -- Methods
Abstract

Author(s): Noe B. Mercado [sup.1] , Roland Zahn [sup.2] , Frank Wegmann [sup.2] , Carolin Loos [sup.3] [sup.4] , Abishek Chandrashekar [sup.1] , Jingyou Yu [sup.1] , Jinyan Liu [sup.1] [...], A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic.sup.1-8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes.sup.9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials. The protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccine expressing the SARS-CoV-2 spike protein in non-human primates is demonstrated.

Published
2020
Full Text
View/download PDF

14. Potently neutralizing and protective human antibodies against SARS-CoV-2

Author

Zost, Seth J., Gilchuk, Pavlo, Case, James Brett, Binshtein, Elad, Chen, Rita E., Nkolola, Joseph P., Schäfer, Alexandra, Reidy, Joseph X., Trivette, Andrew, Nargi, Rachel S., Sutton, Rachel E., Suryadevara, Naveenchandra, Martinez, David R., Williamson, Lauren E., Chen, Elaine C., Jones, Taylor, Day, Samuel, Myers, Luke, Hassan, Ahmed O., Kafai, Natasha M., Winkler, Emma S., Fox, Julie M., Shrihari, Swathi, Mueller, Benjamin K., Meiler, Jens, Chandrashekar, Abishek, Mercado, Noe B., Steinhardt, James J., Ren, Kuishu, Loo, Yueh-Ming, Kallewaard, Nicole L., McCune, Broc T., Keeler, Shamus P., Holtzman, Michael J., Barouch, Dan H., Gralinski, Lisa E., Baric, Ralph S., Thackray, Larissa B., Diamond, Michael S., Carnahan, Robert H., and Crowe, Jr, James E.

Published
2020
Full Text
View/download PDF

15. Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques

Author

Cadena, Anthony M., Ventura, John D., Abbink, Peter, Borducchi, Erica N., Tuyishime, Hubert, Mercado, Noe B., Walker-Sperling, Victoria, Siamatu, Mazuba, Liu, Po-Ting, Chandrashekar, Abishek, Nkolola, Joseph P., McMahan, Katherine, Kordana, Nicole, Hamza, Venous, Bondzie, Esther A., Fray, Emily, Kumar, Mithra, Fischinger, Stephanie, Shin, Sally A., Lewis, Mark G., Siliciano, Robert F., Alter, Galit, and Barouch, Dan H.

Published
2021
Full Text
View/download PDF

16. SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques

Author

Roozendaal, Ramon, Solforosi, Laura, Stieh, Daniel J., Serroyen, Jan, Straetemans, Roel, Dari, Anna, Boulton, Muriel, Wegmann, Frank, Rosendahl Huber, Sietske K., van der Lubbe, Joan E. M., Hendriks, Jenny, Le Gars, Mathieu, Dekking, Liesbeth, Czapska-Casey, Dominika N., Guimera, Nuria, Janssen, Sarah, Tete, Sarah, Chandrashekar, Abishek, Mercado, Noe B., Yu, Jingyou, Koudstaal, Wouter, Perez-Ruixo, Juan J., Sadoff, Jerry, Barouch, Dan H., Schuitemaker, Hanneke, and Zahn, Roland

Published
2021
Full Text
View/download PDF

18. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

Author

Borducchi, Erica N., Liu, Jinyan, Nkolola, Joseph P., Cadena, Anthony M., Yu, Wen-Han, Fischinger, Stephanie, Broge, Thomas, Abbink, Peter, Mercado, Noe B., Chandrashekar, Abishek, Jetton, David, Peter, Lauren, McMahan, Katherine, Moseley, Edward T., Bekerman, Elena, Hesselgesser, Joseph, Li, Wenjun, Lewis, Mark G., Alter, Galit, Geleziunas, Romas, and Barouch, Dan H.

Published
2018
Full Text
View/download PDF

19. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Author

Abbink, Peter, Larocca, Rafael A., De La Barrera, Rafael A., Bricault, Christine A., Moseley, Edward T., Boyd, Michael, Kirilova, Marinela, Li, Zhenfeng, Ng'ang'a, David, Nanayakkara, Ovini, Nityanandam, Ramya, Mercado, Noe B., Borducchi, Erica N., Agarwal, Arshi, Brinkman, Amanda L., Cabral, Crystal, Chandrashekar, Abishek, Giglio, Patricia B., Jetton, David, Jimenez, Jessica, Lee, Benjamin C., Mojta, Shanell, Molloy, Katherine, Shetty, Mayuri, Neubauer, George H., Stephenson, Kathryn E., Peron, Jean Pierre S., de A. Zanotto, Paolo M., Misamore, Johnathan, Finneyfrock, Brad, Lewis, Mark G., Alter, Galit, Modjarrad, Kayvon, Jarman, Richard G., Eckels, Kenneth H., Michael, Nelson L., Thomas, Stephen J., and Barouch, Dan H.

Published
2016

20. Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates

Author

Massachusetts Institute of Technology. Department of Biological Engineering, Zhu, Daniel Y, Gorman, Matthew J, Yuan, Dansu, Yu, Jingyou, Mercado, Noe B, McMahan, Katherine, Borducchi, Erica N, Lifton, Michelle, Liu, Jinyan, Nampanya, Felix, Patel, Shivani, Peter, Lauren, Tostanoski, Lisa H, Pessaint, Laurent, Van Ry, Alex, Finneyfrock, Brad, Velasco, Jason, Teow, Elyse, Brown, Renita, Cook, Anthony, Andersen, Hanne, Lewis, Mark G, Lauffenburger, Douglas A, Barouch, Dan H, Alter, Galit, Massachusetts Institute of Technology. Department of Biological Engineering, Zhu, Daniel Y, Gorman, Matthew J, Yuan, Dansu, Yu, Jingyou, Mercado, Noe B, McMahan, Katherine, Borducchi, Erica N, Lifton, Michelle, Liu, Jinyan, Nampanya, Felix, Patel, Shivani, Peter, Lauren, Tostanoski, Lisa H, Pessaint, Laurent, Van Ry, Alex, Finneyfrock, Brad, Velasco, Jason, Teow, Elyse, Brown, Renita, Cook, Anthony, Andersen, Hanne, Lewis, Mark G, Lauffenburger, Douglas A, Barouch, Dan H, and Alter, Galit

Abstract

Despite the rapid creation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines, the precise correlates of immunity against severe Coronavirus Disease 2019 (COVID-19) are still unknown. Neutralizing antibodies represent a robust surrogate of protection in early Phase III studies, but vaccines provide protection prior to the evolution of neutralization, vaccines provide protection against variants that evade neutralization, and vaccines continue to provide protection against disease severity in the setting of waning neutralizing titers. Thus, in this study, using an Ad26.CoV2.S dose-down approach in nonhuman primates (NHPs), the role of neutralization, Fc effector function, and T-cell immunity were collectively probed against infection as well as against viral control. While dosing-down minimally impacted neutralizing and binding antibody titers, Fc receptor binding and functional antibody levels were induced in a highly dose-dependent manner. Neutralizing antibody and Fc receptor binding titers, but minimally T cells, were linked to the prevention of transmission. Conversely, Fc receptor binding/function and T cells were linked to antiviral control, with a minimal role for neutralization. These data point to dichotomous roles of neutralization and T-cell function in protection against transmission and disease severity and a continuous role for Fc effector function as a correlate of immunity key to halting and controlling SARS-CoV-2 and emerging variants.

Published
2023

21. Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Author

Mercado, Noe B., Zahn, Roland, Wegmann, Frank, Loos, Carolin, Chandrashekar, Abishek, Yu, Jingyou, Liu, Jinyan, Peter, Lauren, McMahan, Katherine, Tostanoski, Lisa H., He, Xuan, Martinez, David R., Rutten, Lucy, Bos, Rinke, van Manen, Danielle, Vellinga, Jort, Custers, Jerome, Langedijk, Johannes P., Kwaks, Ted, Bakkers, Mark J. G., Zuijdgeest, David, Huber, Sietske K. Rosendahl, Atyeo, Caroline, Fischinger, Stephanie, Burke, John S., Feldman, Jared, Hauser, Blake M., Caradonna, Timothy M., Bondzie, Esther A., Dagotto, Gabriel, Gebre, Makda S., Hoffman, Emily, Jacob-Dolan, Catherine, Kirilova, Marinela, Li, Zhenfeng, Lin, Zijin, Mahrokhian, Shant H., Maxfield, Lori F., Nampanya, Felix, Nityanandam, Ramya, Nkolola, Joseph P., Patel, Shivani, Ventura, John D., Verrington, Kaylee, Wan, Huahua, Pessaint, Laurent, Van Ry, Alex, Blade, Kelvin, Strasbaugh, Amanda, Cabus, Mehtap, Brown, Renita, Cook, Anthony, Zouantchangadou, Serge, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Cai, Yongfei, Chen, Bing, Schmidt, Aaron G., Reeves, R. Keith, Baric, Ralph S., Lauffenburger, Douglas A., Alter, Galit, Stoffels, Paul, Mammen, Mathai, Van Hoof, Johan, Schuitemaker, Hanneke, and Barouch, Dan H.

Published
2021
Full Text
View/download PDF

22. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys

Author

Abbink, Peter, Larocca, Rafael A., Visitsunthorn, Kittipos, Boyd, Michael, De La Barrera, Rafael A., Gromowski, Gregory D., Kirilova, Marinela, Peterson, Rebecca, Li, Zhenfeng, Nanayakkara, Ovini, Nityanandam, Ramya, Mercado, Noe B., Borducchi, Erica N., Chandrashekar, Abishek, Jetton, David, Mojta, Shanell, Gandhi, Priya, LeSuer, Jake, Khatiwada, Shreeya, Lewis, Mark G., Modjarrad, Kayvon, Jarman, Richard G., Eckels, Kenneth H., Thomas, Stephen J., Michael, Nelson L., and Barouch, Dan H.

Published
2017
Full Text
View/download PDF

23. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

Author

Julg, Boris, Liu, Po-Ting, Wagh, Kshitij, Fischer, William M., Abbink, Peter, Mercado, Noe B., Whitney, James B., Nkolola, Joseph P., McMahan, Katherine, Tartaglia, Lawrence J., Borducchi, Erica N., Khatiwada, Shreeya, Kamath, Megha, LeSuer, Jake A., Seaman, Michael S., Schmidt, Stephen D., Mascola, John R., Burton, Dennis R., Korber, Bette T., and Barouch, Dan H.

Published
2017
Full Text
View/download PDF

24. Vaccine protection against Zika virus from Brazil

Author

Larocca, Rafael A., Abbink, Peter, Peron, Jean Pierre S., de A. Zanotto, Paolo M., Iampietro, M. Justin, Badamchi-Zadeh, Alexander, Boyd, Michael, Nganga, David, Kirilova, Marinela, Nityanandam, Ramya, Mercado, Noe B., Li, Zhenfeng, Moseley, Edward T., Bricault, Christine A., Borducchi, Erica N., Giglio, Patricia B., Jetton, David, Neubauer, George, Nkolola, Joseph P., Maxfield, Lori F., De La Barrera, Rafael A., Jarman, Richard G., Eckels, Kenneth H., Michael, Nelson L., Thomas, Stephen J., and Barouch, Dan H.

Subjects
Prevention, Product development, Zika virus infection -- Prevention, Viral vaccines -- Product development
Abstract

Author(s): Rafael A. Larocca [1]; Peter Abbink [1]; Jean Pierre S. Peron [2]; Paolo M. de A. Zanotto [2]; M. Justin Iampietro [1]; Alexander Badamchi-Zadeh [1]; Michael Boyd [1]; David [...]

Published
2016
Full Text
View/download PDF

25. Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments

Author

Piedra-Mora, Cesar, primary, Robinson, Sally R., additional, Tostanoski, Lisa H., additional, Dayao, Denise A. E., additional, Chandrashekar, Abishek, additional, Bauer, Katherine, additional, Wrijil, Linda, additional, Ducat, Sarah, additional, Hayes, Tammy, additional, Yu, Jingyou, additional, Bondzie, Esther A., additional, McMahan, Katherine, additional, Sellers, Daniel, additional, Giffin, Victoria, additional, Hope, David, additional, Nampanya, Felix, additional, Mercado, Noe B., additional, Kar, Swagata, additional, Andersen, Hanne, additional, Tzipori, Saul, additional, Barouch, Dan H., additional, and Martinot, Amanda J., additional

Published
2022
Full Text
View/download PDF

26. Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates

Author

Zhu, Daniel Y., primary, Gorman, Matthew J., additional, Yuan, Dansu, additional, Yu, Jingyou, additional, Mercado, Noe B., additional, McMahan, Katherine, additional, Borducchi, Erica N., additional, Lifton, Michelle, additional, Liu, Jinyan, additional, Nampanya, Felix, additional, Patel, Shivani, additional, Peter, Lauren, additional, Tostanoski, Lisa H., additional, Pessaint, Laurent, additional, Van Ry, Alex, additional, Finneyfrock, Brad, additional, Velasco, Jason, additional, Teow, Elyse, additional, Brown, Renita, additional, Cook, Anthony, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, Lauffenburger, Douglas A., additional, Barouch, Dan H., additional, and Alter, Galit, additional

Published
2022
Full Text
View/download PDF

27. SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques

Author

Dalvie, Neil C., primary, Tostanoski, Lisa H., additional, Rodriguez-Aponte, Sergio A., additional, Kaur, Kawaljit, additional, Bajoria, Sakshi, additional, Kumru, Ozan S., additional, Martinot, Amanda J., additional, Chandrashekar, Abishek, additional, McMahan, Katherine, additional, Mercado, Noe B., additional, Yu, Jingyou, additional, Chang, Aiquan, additional, Giffin, Victoria M., additional, Nampanya, Felix, additional, Patel, Shivani, additional, Bowman, Lesley, additional, Naranjo, Christopher A., additional, Yun, Dongsoo, additional, Flinchbaugh, Zach, additional, Pessaint, Laurent, additional, Brown, Renita, additional, Velasco, Jason, additional, Teow, Elyse, additional, Cook, Anthony, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, Camp, Danielle L., additional, Silverman, Judith Maxwell, additional, Nagar, Gaurav S., additional, Rao, Harish D., additional, Lothe, Rakesh R., additional, Chandrasekharan, Rahul, additional, Rajurkar, Meghraj P., additional, Shaligram, Umesh S., additional, Kleanthous, Harry, additional, Joshi, Sangeeta B., additional, Volkin, David B., additional, Biswas, Sumi, additional, Love, J. Christopher, additional, and Barouch, Dan H., additional

Published
2022
Full Text
View/download PDF

28. Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

Author

Borducchi, Erica N., Liu, Jinyan, Nkolola, Joseph P., Cadena, Anthony M., Yu, Wen-Han, Fischinger, Stephanie, Broge, Thomas, Abbink, Peter, Mercado, Noe B., Chandrashekar, Abishek, Jetton, David, Peter, Lauren, McMahan, Katherine, Moseley, Edward T., Bekerman, Elena, Hesselgesser, Joseph, Li, Wenjun, Lewis, Mark G., Alter, Galit, Geleziunas, Romas, and Barouch, Dan H.

Published
2018
Full Text
View/download PDF

29. Long-acting capsid inhibitor protects macaques from repeat SHIV challenges

Author

Vidal, Samuel J., primary, Bekerman, Elena, additional, Hansen, Derek, additional, Lu, Bing, additional, Wang, Kelly, additional, Mwangi, Judy, additional, Rowe, William, additional, Campigotto, Federico, additional, Zheng, Jim, additional, Kato, Darryl, additional, Chandrashekar, Abishek, additional, Barrett, Julia, additional, Patel, Shivani, additional, Wan, Huahua, additional, Anioke, Tochi, additional, Mercado, Noe B., additional, Nkolola, Joseph P., additional, Ferguson, Melissa J., additional, Rinaldi, William J., additional, Callebaut, Christian, additional, Blair, Wade, additional, Cihlar, Tomas, additional, Geleziunas, Romas, additional, Yant, Stephen R., additional, and Barouch, Dan H., additional

Published
2021
Full Text
View/download PDF

30. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

Author

Gebre, Makda S., primary, Rauch, Susanne, additional, Roth, Nicole, additional, Yu, Jingyou, additional, Chandrashekar, Abishek, additional, Mercado, Noe B., additional, He, Xuan, additional, Liu, Jinyan, additional, McMahan, Katherine, additional, Martinot, Amanda, additional, Martinez, David R., additional, Giffin, Victoria, additional, Hope, David, additional, Patel, Shivani, additional, Sellers, Daniel, additional, Sanborn, Owen, additional, Barrett, Julia, additional, Liu, Xiaowen, additional, Cole, Andrew C., additional, Pessaint, Laurent, additional, Valentin, Daniel, additional, Flinchbaugh, Zack, additional, Yalley-Ogunro, Jake, additional, Muench, Jeanne, additional, Brown, Renita, additional, Cook, Anthony, additional, Teow, Elyse, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, Boon, Adrianus C. M., additional, Baric, Ralph S., additional, Mueller, Stefan O., additional, Petsch, Benjamin, additional, and Barouch, Dan H., additional

Published
2021
Full Text
View/download PDF

31. Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern

Author

Tostanoski, Lisa H., primary, Yu, Jingyou, additional, Mercado, Noe B., additional, McMahan, Katherine, additional, Jacob-Dolan, Catherine, additional, Martinot, Amanda J., additional, Piedra-Mora, Cesar, additional, Anioke, Tochi, additional, Chang, Aiquan, additional, Giffin, Victoria M., additional, Hope, David L., additional, Wan, Huahua, additional, Bondzie, Esther A., additional, Mahrokhian, Shant H., additional, Wrijil, Linda M., additional, Bauer, Katherine, additional, Pessaint, Laurent, additional, Porto, Maciel, additional, Piegols, Joseph, additional, Faudree, Andrew, additional, Spence, Brittany, additional, Kar, Swagata, additional, Amanat, Fatima, additional, Krammer, Florian, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, Wegmann, Frank, additional, Zahn, Roland, additional, Schuitemaker, Hanneke, additional, and Barouch, Dan H., additional

Published
2021
Full Text
View/download PDF

32. Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants

Author

Chandrashekar, Abishek, primary, Liu, Jinyan, additional, Yu, Jingyou, additional, McMahan, Katherine, additional, Tostanoski, Lisa H., additional, Jacob-Dolan, Catherine, additional, Mercado, Noe B., additional, Anioke, Tochi, additional, Chang, Aiquan, additional, Gardner, Sarah, additional, Giffin, Victoria M., additional, Hope, David L., additional, Nampanya, Felix, additional, Patel, Shivani, additional, Sanborn, Owen, additional, Sellers, Daniel, additional, Wan, Huahua, additional, Martinot, Amanda J., additional, Baczenas, John J., additional, O’Connor, Shelby L., additional, Pessaint, Laurent, additional, Valentin, Daniel, additional, Espina, Benjamin, additional, Wattay, Lauren, additional, Ferrari, Maria G., additional, Brown, Renita, additional, Cook, Anthony, additional, Bueno-Wilkerson, Deandre, additional, Teow, Elyse, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, and Barouch, Dan H., additional

Published
2021
Full Text
View/download PDF

33. Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques

Author

Yu, Jingyou, primary, Collins, Natalie D., additional, Mercado, Noe B., additional, McMahan, Katherine, additional, Chandrashekar, Abishek, additional, Liu, Jinyan, additional, Anioke, Tochi, additional, Chang, Aiquan, additional, Giffin, Victoria M., additional, Hope, David L., additional, Sellers, Daniel, additional, Nampanya, Felix, additional, Gardner, Sarah, additional, Barrett, Julia, additional, Wan, Huahua, additional, Velasco, Jason, additional, Teow, Elyse, additional, Cook, Anthony, additional, Van Ry, Alex, additional, Pessaint, Laurent, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, Hofer, Christian, additional, Burke, Donald S., additional, Barkei, Erica K., additional, King, Hannah A.D., additional, Subra, Caroline, additional, Bolton, Diane, additional, Modjarrad, Kayvon, additional, Michael, Nelson L., additional, and Barouch, Dan H., additional

Published
2021
Full Text
View/download PDF

34. Increased IL-6 expression precedes reliable viral detection in the rhesus macaque brain during acute SIV infection

Author

Gopalakrishnan, Raja Mohan, primary, Aid, Malika, additional, Mercado, Noe B., additional, Davis, Caitlin, additional, Malik, Shaily, additional, Geiger, Emma, additional, Varner, Valerie, additional, Jones, Rhianna, additional, Bosinger, Steven E., additional, Piedra-Mora, Cesar, additional, Martinot, Amanda J., additional, Barouch, Dan H., additional, Reeves, R. Keith, additional, and Tan, C. Sabrina, additional

Published
2021
Full Text
View/download PDF

35. Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates

Author

Gebre, Makda S., primary, Rauch, Susanne, additional, Roth, Nicole, additional, Yu, Jingyou, additional, Chandrashekar, Abishek, additional, Mercado, Noe B., additional, He, Xuan, additional, Liu, Jinyan, additional, McMahan, Katherine, additional, Martinot, Amanda, additional, Giffin, Tori, additional, Hope, David, additional, Patel, Shivani, additional, Sellers, Daniel, additional, Sanborn, Owen, additional, Barrett, Julia, additional, Liu, Xiaowen, additional, Cole, Andrew C., additional, Pessaint, Laurent, additional, Valentin, Daniel, additional, Flinchbaugh, Zack, additional, Yalley-Ogunro, Jake, additional, Muench, Jeanne, additional, Brown, Renita, additional, Cook, Anthony, additional, Teow, Elyse, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, Mueller, Stefan O., additional, Petsch, Benjamin, additional, and Barouch, Dan H., additional

Published
2021
Full Text
View/download PDF

36. A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates

Author

Dalvie, Neil C., primary, Tostanoski, Lisa H., additional, Rodriguez-Aponte, Sergio A, additional, Kaur, Kawaljit, additional, Bajoria, Sakshi, additional, Kumru, Ozan S., additional, Martinot, Amanda J., additional, Chandrashekar, Abishek, additional, McMahan, Katherine, additional, Mercado, Noe B., additional, Yu, Jingyou, additional, Chang, Aiquan, additional, Giffin, Victoria M., additional, Nampanya, Felix, additional, Patel, Shivani, additional, Bowman, Lesley, additional, Naranjo, Christopher A., additional, Yun, Dongsoo, additional, Flinchbaugh, Zach, additional, Pessaint, Laurent, additional, Brown, Renita, additional, Velasco, Jason, additional, Teow, Elyse, additional, Cook, Anthony, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, Camp, Danielle L., additional, Silverman, Judith Maxwell, additional, Kleanthous, Harry, additional, Joshi, Sangeeta B., additional, Volkin, David B., additional, Biswas, Sumi, additional, Love, J. Christopher, additional, and Barouch, Dan H., additional

Published
2021
Full Text
View/download PDF

37. Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques

Author

Massachusetts Institute of Technology. Department of Biological Engineering, Alter, Galit, Yu, Wen-Han, Chandrashekar, Abishek, Borducchi, Erica N., Ghneim, Khader, Sharma, Ashish, Nedellec, Rebecca, McKenney, Katherine R., Linde, Caitlyn, Broge, Thomas, Suscovich, Todd J., Linnekin, Tom, Abbink, Peter, Mercado, Noe B., Nkolola, Joseph P., McMahan, Katherine, Bondzie, Esther A., Hamza, Venous, Peter, Lauren, Kordana, Nicole, Mahrokhian, Shant, Seaman, Michael S., Li, Wenjun, Lewis, Mark G., Lauffenburger, Douglas A, Hangartner, Lars, Sekaly, Rafick-Pierre, Barouch, Dan H., Massachusetts Institute of Technology. Department of Biological Engineering, Alter, Galit, Yu, Wen-Han, Chandrashekar, Abishek, Borducchi, Erica N., Ghneim, Khader, Sharma, Ashish, Nedellec, Rebecca, McKenney, Katherine R., Linde, Caitlyn, Broge, Thomas, Suscovich, Todd J., Linnekin, Tom, Abbink, Peter, Mercado, Noe B., Nkolola, Joseph P., McMahan, Katherine, Bondzie, Esther A., Hamza, Venous, Peter, Lauren, Kordana, Nicole, Mahrokhian, Shant, Seaman, Michael S., Li, Wenjun, Lewis, Mark G., Lauffenburger, Douglas A, Hangartner, Lars, Sekaly, Rafick-Pierre, and Barouch, Dan H.

Abstract

Several HIV-1 and SIV vaccine candidates have shown partial protection against viral challenges in rhesus macaques. However, the protective efficacy of vaccine-elicited polyclonal antibodies has not previously been demonstrated in adoptive transfer studies in nonhuman primates. In this study, we show that passive transfer of purified antibodies from vaccinated macaques can protect naive animals against SIVmac251 challenges. We vaccinated 30 rhesus macaques with Ad26-SIV Env/Gag/Pol and SIV Env gp140 protein vaccines and assessed the induction of antibody responses and a putative protective signature. This signature included multiple antibody functions and correlated with upregulation of interferon pathways in vaccinated animals. Adoptive transfer of purified immunoglobulin G (IgG) from the vaccinated animals with the most robust protective signatures provided partial protection against SIVmac251 challenges in naive recipient rhesus macaques. These data demonstrate the protective efficacy of purified vaccine-elicited antiviral antibodies in this model, even in the absence of virus neutralization., National Institutes of Health (Grants AI060354, AI080289, AI102660, AI124377, AI126603, AI128751, AI129797, OD024917)

Published
2021

38. Correlates of protection against SARS-CoV-2 in rhesus macaques

Author

Ragon Institute of MGH, MIT and Harvard, Massachusetts Institute of Technology. Department of Biological Engineering, McMahan, Katherine, Yu, Jingyou, Mercado, Noe B., Loos, Carolin, Tostanoski, Lisa H., Chandrashekar, Abishek, Liu, Jinyan, Peter, Lauren, Atyeo, Caroline, Zhu, Alex Lee, Bondzie, Esther A., Dagotto, Gabriel, Gebre, Makda S., Jacob-Dolan, Catherine, Li, Zhenfeng, Nampanya, Felix, Patel, Shivani, Pessaint, Laurent, Van Ry, Alex, Blade, Kelvin, Yalley-Ogunro, Jake, Cabus, Mehtap, Brown, Renita, Cook, Anthony, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Lauffenburger, Douglas A, Alter, Galit, Barouch, Dan H., Ragon Institute of MGH, MIT and Harvard, Massachusetts Institute of Technology. Department of Biological Engineering, McMahan, Katherine, Yu, Jingyou, Mercado, Noe B., Loos, Carolin, Tostanoski, Lisa H., Chandrashekar, Abishek, Liu, Jinyan, Peter, Lauren, Atyeo, Caroline, Zhu, Alex Lee, Bondzie, Esther A., Dagotto, Gabriel, Gebre, Makda S., Jacob-Dolan, Catherine, Li, Zhenfeng, Nampanya, Felix, Patel, Shivani, Pessaint, Laurent, Van Ry, Alex, Blade, Kelvin, Yalley-Ogunro, Jake, Cabus, Mehtap, Brown, Renita, Cook, Anthony, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Lauffenburger, Douglas A, Alter, Galit, and Barouch, Dan H.

Abstract

Recent studies have reported the protective efficacy of both natural1 and vaccine-induced2–7 immunity against challenge with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques. However, the importance of humoral and cellular immunity for protection against infection with SARS-CoV-2 remains to be determined. Here we show that the adoptive transfer of purified IgG from convalescent rhesus macaques (Macaca mulatta) protects naive recipient macaques against challenge with SARS-CoV-2 in a dose-dependent fashion. Depletion of CD8+ T cells in convalescent macaques partially abrogated the protective efficacy of natural immunity against rechallenge with SARS-CoV-2, which suggests a role for cellular immunity in the context of waning or subprotective antibody titres. These data demonstrate that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune responses may contribute to protection if antibody responses are suboptimal. We also show that higher antibody titres are required for treatment of SARS-CoV-2 infection in macaques. These findings have implications for the development of SARS-CoV-2 vaccines and immune-based therapeutic agents., Bill & Melinda Gates Foundation (Grant INV-006131), National Institutes of Health (Grants OD024917, AI129797, AI124377, AI128751, AI126603 and CA260476)

Published
2021

39. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Author

Ragon Institute of MGH, MIT and Harvard, Massachusetts Institute of Technology. Department of Biological Engineering, Mercado, Noe B., Zahn, Roland, Wegmann, Frank, Loos, Carolin, Chandrashekar, Abishek, Yu, Jingyou, Liu, Jinyan, Peter, Lauren, McMahan, Katherine, Tostanoski, Lisa H., He, Xuan, Martinez, David R., Rutten, Lucy, Bos, Rinke, van Manen, Danielle, Vellinga, Jort, Custers, Jerome, Langedijk, Johannes P., Kwaks, Ted, Bakkers, Mark J. G., Zuijdgeest, David, Rosendahl Huber, Sietske K., Atyeo, Caroline, Fischinger, Stephanie, Burke, John, Feldman, Jared, Hauser, Blake Marie, Caradonna, Timothy M., Bondzie, Esther A., Dagotto, Gabriel, Gebre, Makda S., Hoffman, Emily, Jacob-Dolan, Catherine, Kirilova, Marinela, Li, Zhenfeng, Lin, Zijin, Mahrokhian, Shant H., Maxfield, Lori F., Nampanya, Felix, Nityanandam, Ramya, Nkolola, Joseph P., Patel, Shivani, Ventura, John D., Verrington, Kaylee, Wan, Huahua, Pessaint, Laurent, Van Ry, Alex, Blade, Kelvin, Strasbaugh, Amanda, Cabus, Mehtap, Brown, Renita, Cook, Anthony, Zouantchangadou, Serge, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Cai, Yongfei, Chen, Bing, Schmidt, Aaron G., Reeves, R. Keith, Baric, Ralph S., Lauffenburger, Douglas A., Alter, Galit, Stoffels, Paul, Mammen, Mathai, Van Hoof, Johan, Schuitemaker, Hanneke, Barouch, Dan, Ragon Institute of MGH, MIT and Harvard, Massachusetts Institute of Technology. Department of Biological Engineering, Mercado, Noe B., Zahn, Roland, Wegmann, Frank, Loos, Carolin, Chandrashekar, Abishek, Yu, Jingyou, Liu, Jinyan, Peter, Lauren, McMahan, Katherine, Tostanoski, Lisa H., He, Xuan, Martinez, David R., Rutten, Lucy, Bos, Rinke, van Manen, Danielle, Vellinga, Jort, Custers, Jerome, Langedijk, Johannes P., Kwaks, Ted, Bakkers, Mark J. G., Zuijdgeest, David, Rosendahl Huber, Sietske K., Atyeo, Caroline, Fischinger, Stephanie, Burke, John, Feldman, Jared, Hauser, Blake Marie, Caradonna, Timothy M., Bondzie, Esther A., Dagotto, Gabriel, Gebre, Makda S., Hoffman, Emily, Jacob-Dolan, Catherine, Kirilova, Marinela, Li, Zhenfeng, Lin, Zijin, Mahrokhian, Shant H., Maxfield, Lori F., Nampanya, Felix, Nityanandam, Ramya, Nkolola, Joseph P., Patel, Shivani, Ventura, John D., Verrington, Kaylee, Wan, Huahua, Pessaint, Laurent, Van Ry, Alex, Blade, Kelvin, Strasbaugh, Amanda, Cabus, Mehtap, Brown, Renita, Cook, Anthony, Zouantchangadou, Serge, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Cai, Yongfei, Chen, Bing, Schmidt, Aaron G., Reeves, R. Keith, Baric, Ralph S., Lauffenburger, Douglas A., Alter, Galit, Stoffels, Paul, Mammen, Mathai, Van Hoof, Johan, Schuitemaker, Hanneke, and Barouch, Dan

Abstract

A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1–8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.

Published
2021

41. Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques

Author

He, Xuan, primary, Chandrashekar, Abishek, additional, Zahn, Roland, additional, Wegmann, Frank, additional, Yu, Jingyou, additional, Mercado, Noe B., additional, McMahan, Katherine, additional, Martinot, Amanda J., additional, Piedra-Mora, Cesar, additional, Beecy, Sidney, additional, Ducat, Sarah, additional, Chamanza, Ronnie, additional, Huber, Sietske Rosendahl, additional, van der Fits, Leslie, additional, Borducchi, Erica N., additional, Lifton, Michelle, additional, Liu, Jinyan, additional, Nampanya, Felix, additional, Patel, Shivani, additional, Peter, Lauren, additional, Tostanoski, Lisa H., additional, Pessaint, Laurent, additional, Van Ry, Alex, additional, Finneyfrock, Brad, additional, Velasco, Jason, additional, Teow, Elyse, additional, Brown, Renita, additional, Cook, Anthony, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, Schuitemaker, Hanneke, additional, and Barouch, Dan H., additional

Published
2021
Full Text
View/download PDF

42. Correlates of protection against SARS-CoV-2 in rhesus macaques

Author

McMahan, Katherine, primary, Yu, Jingyou, additional, Mercado, Noe B., additional, Loos, Carolin, additional, Tostanoski, Lisa H., additional, Chandrashekar, Abishek, additional, Liu, Jinyan, additional, Peter, Lauren, additional, Atyeo, Caroline, additional, Zhu, Alex, additional, Bondzie, Esther A., additional, Dagotto, Gabriel, additional, Gebre, Makda S., additional, Jacob-Dolan, Catherine, additional, Li, Zhenfeng, additional, Nampanya, Felix, additional, Patel, Shivani, additional, Pessaint, Laurent, additional, Van Ry, Alex, additional, Blade, Kelvin, additional, Yalley-Ogunro, Jake, additional, Cabus, Mehtap, additional, Brown, Renita, additional, Cook, Anthony, additional, Teow, Elyse, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, Lauffenburger, Douglas A., additional, Alter, Galit, additional, and Barouch, Dan H., additional

Published
2020
Full Text
View/download PDF

43. Feasibility and safety of ultrasound-guided minimally invasive autopsy in COVID-19 patients

Author

Brook, Olga R., primary, Piper, Kimberly G., additional, Mercado, Noe B., additional, Gebre, Makda S., additional, Barouch, Dan H., additional, Busman-Sahay, Kathleen, additional, Starke, Carly E., additional, Estes, Jacob D., additional, Martinot, Amanda J., additional, Wrijil, Linda, additional, Ducat, Sarah, additional, and Hecht, Jonathan L., additional

Published
2020
Full Text
View/download PDF

44. DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Author

Yu, Jingyou, primary, Tostanoski, Lisa H., additional, Peter, Lauren, additional, Mercado, Noe B., additional, McMahan, Katherine, additional, Mahrokhian, Shant H., additional, Nkolola, Joseph P., additional, Liu, Jinyan, additional, Li, Zhenfeng, additional, Chandrashekar, Abishek, additional, Martinez, David R., additional, Loos, Carolin, additional, Atyeo, Caroline, additional, Fischinger, Stephanie, additional, Burke, John S., additional, Slein, Matthew D., additional, Chen, Yuezhou, additional, Zuiani, Adam, additional, Lelis, Felipe J. N., additional, Travers, Meghan, additional, Habibi, Shaghayegh, additional, Pessaint, Laurent, additional, Van Ry, Alex, additional, Blade, Kelvin, additional, Brown, Renita, additional, Cook, Anthony, additional, Finneyfrock, Brad, additional, Dodson, Alan, additional, Teow, Elyse, additional, Velasco, Jason, additional, Zahn, Roland, additional, Wegmann, Frank, additional, Bondzie, Esther A., additional, Dagotto, Gabriel, additional, Gebre, Makda S., additional, He, Xuan, additional, Jacob-Dolan, Catherine, additional, Kirilova, Marinela, additional, Kordana, Nicole, additional, Lin, Zijin, additional, Maxfield, Lori F., additional, Nampanya, Felix, additional, Nityanandam, Ramya, additional, Ventura, John D., additional, Wan, Huahua, additional, Cai, Yongfei, additional, Chen, Bing, additional, Schmidt, Aaron G., additional, Wesemann, Duane R., additional, Baric, Ralph S., additional, Alter, Galit, additional, Andersen, Hanne, additional, Lewis, Mark G., additional, and Barouch, Dan H., additional

Published
2020
Full Text
View/download PDF

45. SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Author

Chandrashekar, Abishek, primary, Liu, Jinyan, additional, Martinot, Amanda J., additional, McMahan, Katherine, additional, Mercado, Noe B., additional, Peter, Lauren, additional, Tostanoski, Lisa H., additional, Yu, Jingyou, additional, Maliga, Zoltan, additional, Nekorchuk, Michael, additional, Busman-Sahay, Kathleen, additional, Terry, Margaret, additional, Wrijil, Linda M., additional, Ducat, Sarah, additional, Martinez, David R., additional, Atyeo, Caroline, additional, Fischinger, Stephanie, additional, Burke, John S., additional, Slein, Matthew D., additional, Pessaint, Laurent, additional, Van Ry, Alex, additional, Greenhouse, Jack, additional, Taylor, Tammy, additional, Blade, Kelvin, additional, Cook, Anthony, additional, Finneyfrock, Brad, additional, Brown, Renita, additional, Teow, Elyse, additional, Velasco, Jason, additional, Zahn, Roland, additional, Wegmann, Frank, additional, Abbink, Peter, additional, Bondzie, Esther A., additional, Dagotto, Gabriel, additional, Gebre, Makda S., additional, He, Xuan, additional, Jacob-Dolan, Catherine, additional, Kordana, Nicole, additional, Li, Zhenfeng, additional, Lifton, Michelle A., additional, Mahrokhian, Shant H., additional, Maxfield, Lori F., additional, Nityanandam, Ramya, additional, Nkolola, Joseph P., additional, Schmidt, Aaron G., additional, Miller, Andrew D., additional, Baric, Ralph S., additional, Alter, Galit, additional, Sorger, Peter K., additional, Estes, Jacob D., additional, Andersen, Hanne, additional, Lewis, Mark G., additional, and Barouch, Dan H., additional

Published
2020
Full Text
View/download PDF

46. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C

Author

Tartaglia, Lawrence J., primary, Gupte, Siddhant, additional, Pastores, Kevin C., additional, Trott, Sebastien, additional, Abbink, Peter, additional, Mercado, Noe B., additional, Li, Zhenfeng, additional, Liu, Po-Ting, additional, Borducchi, Erica N., additional, Chandrashekar, Abishek, additional, Bondzie, Esther Apraku, additional, Hamza, Venous, additional, Kordana, Nicole, additional, Mahrokhian, Shant, additional, Lavine, Christy L., additional, Seaman, Michael S., additional, Li, Hui, additional, Shaw, George M., additional, and Barouch, Dan H., additional

Published
2020
Full Text
View/download PDF

47. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Author

Massachusetts Institute of Technology. Department of Biological Engineering, Tostanoski, Lisa H., Wegmann, Frank, Martinot, Amanda J., Loos, Carolin, McMahan, Katherine, Mercado, Noe B., Yu, Jingyou, Chan, Chi N., Bondoc, Stephen, Starke, Carly E., Nekorchuk, Michael, Busman-Sahay, Kathleen, Piedra-Mora, Cesar, Wrijil, Linda M., Ducat, Sarah, Custers, Jerome, Atyeo, Caroline, Fischinger, Stephanie, Burke, John S., Feldman, Jared, Hauser, Blake M., Caradonna, Timothy M., Bondzie, Esther A., Dagotto, Gabriel, Gebre, Makda S., Jacob-Dolan, Catherine, Lin, Zijin, Mahrokhian, Shant H., Nampanya, Felix, Nityanandam, Ramya, Pessaint, Laurent, Porto, Maciel, Ali, Vaneesha, Benetiene, Dalia, Tevi, Komlan, Andersen, Hanne, Lewis, Mark G., Schmidt, Aaron G., Lauffenburger, Douglas A, Alter, Galit, Estes, Jacob D., Schuitemaker, Hanneke, Zahn, Roland, Barouch, Dan H., Massachusetts Institute of Technology. Department of Biological Engineering, Tostanoski, Lisa H., Wegmann, Frank, Martinot, Amanda J., Loos, Carolin, McMahan, Katherine, Mercado, Noe B., Yu, Jingyou, Chan, Chi N., Bondoc, Stephen, Starke, Carly E., Nekorchuk, Michael, Busman-Sahay, Kathleen, Piedra-Mora, Cesar, Wrijil, Linda M., Ducat, Sarah, Custers, Jerome, Atyeo, Caroline, Fischinger, Stephanie, Burke, John S., Feldman, Jared, Hauser, Blake M., Caradonna, Timothy M., Bondzie, Esther A., Dagotto, Gabriel, Gebre, Makda S., Jacob-Dolan, Catherine, Lin, Zijin, Mahrokhian, Shant H., Nampanya, Felix, Nityanandam, Ramya, Pessaint, Laurent, Porto, Maciel, Ali, Vaneesha, Benetiene, Dalia, Tevi, Komlan, Andersen, Hanne, Lewis, Mark G., Schmidt, Aaron G., Lauffenburger, Douglas A, Alter, Galit, Estes, Jacob D., Schuitemaker, Hanneke, Zahn, Roland, and Barouch, Dan H.

Abstract

Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters and nonhuman primates have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis.

Published
2020

48. Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice

Author

Badamchi-Zadeh, Alexander, primary, Tartaglia, Lawrence J., additional, Abbink, Peter, additional, Bricault, Christine A., additional, Liu, Po-Ting, additional, Boyd, Michael, additional, Kirilova, Marinela, additional, Mercado, Noe B., additional, Nanayakkara, Ovini S., additional, Vrbanac, Vladimir D., additional, Tager, Andrew M., additional, Larocca, Rafael A., additional, Seaman, Michael S., additional, and Barouch, Dan H., additional

Published
2018
Full Text
View/download PDF

49. Lack of therapeutic efficacy of an antibody to α4b7 in SIVmac251-infected rhesus macaques.

Author

Abbink, Peter, Mercado, Noe B., Nkolola, Joseph P., Peterson, Rebecca L., Tuyishime, Hubert, McMahan, Katherine, Moseley, Edward T., Borducchi, Erica N., Chandrashekar, Abishek, Bondzie, Esther A., Agarwal, Arshi, Belli, Aaron J., Reimann, Keith A., Keele, Brandon F., Geleziunas, Romas, Lewis, Mark G., and Barouch, Dan H.

Subjects
*SIMIAN immunodeficiency virus, *RHESUS monkeys, *HIV, *ANTIRETROVIRAL agents, *STOP codons
Abstract

Sustained virologic control of human immunodeficiency virus type 1 (HIV-1) infection after discontinuation of antiretroviral therapy (ART) is a major goal of the HIV-1 cure field. A recent study reported that administration of an antibody against a4b7 induced durable virologic control after ART discontinuation in 100% of rhesus macaques infected with an attenuated strain of simian immunodeficiency virus (SIV) containing a stop codon in nef. We performed similar studies in 50 rhesus macaques infected with wild-type, pathogenic SIVmac251. In animals that initiated ART during either acute or chronic infection, anti-a4b7 antibody infusion had no detectable effect on the viral reservoir or viral rebound after ART discontinuation. These data demonstrate that anti-a4b7 antibody administration did not provide therapeutic efficacy in the model of pathogenic SIVmac251 infection of rhesus macaques. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

50. Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice

Author

Badamchi-Zadeh, Alexander, Tartaglia, Lawrence, Bricault, Christine, Liu, Po-Ting, Larocca, Rafael, Seaman, Michael, Barouch, Dan, Abbink, Peter, Boyd, Michael, Kirilova, Marinela, Mercado, Noe B., Nanayakkara, Ovini S., Vrbanac, Vladimir D., and Tager, Andrew M.

Subjects
HIV-1, PGT121, adeno-associated virus, adenoviruses, neutralizing antibodies
Abstract

Broadly neutralizing antibodies (bNAbs) are being explored for HIV-1 prevention and cure strategies. However, administration of purified bNAbs poses challenges in resource-poor settings, where the HIV-1 disease burden is greatest. In vivo vector-based production of bNAbs represents an alternative strategy. We investigated adenovirus serotype 5 (Ad5) and adeno-associated virus serotype 1 (AAV1) vectors to deliver the HIV-1-specific bNAb PGT121 in wild-type and immunocompromised C57BL/6 mice as well as in HIV-1-infected bone marrow-liver-thymus (BLT) humanized mice. Ad5.PGT121 and AAV1.PGT121 produced functional antibody in vivo. Ad5.PGT121 produced PGT121 rapidly within 6 h, whereas AAV1.PGT121 produced detectable PGT121 in serum by 72 h. Serum PGT121 levels were rapidly reduced by the generation of anti-PGT121 antibodies in immunocompetent mice but were durably maintained in immunocompromised mice. In HIV-1-infected BLT humanized mice, Ad5.PGT121 resulted in a greater reduction of viral loads than did AAV1.PGT121. Ad5.PGT121 also led to more-sustained virologic control than purified PGT121 IgG. Ad5.PGT121 afforded more rapid, robust, and durable antiviral efficacy than AAV1.PGT121 and purified PGT121 IgG in HIV-1-infected humanized mice. Further evaluation of vector delivery of HIV-1 bNAbs is warranted, although approaches to prevent the generation of antiantibody responses may also be required. IMPORTANCE: Broadly neutralizing antibodies (bNAbs) are being explored for HIV-1 prevention and cure strategies, but delivery of purified antibodies may prove challenging. We investigated adenovirus serotype 5 (Ad5) and adeno-associated virus serotype 1 (AAV1) vectors to deliver the HIV-1-specific bNAb PGT121. Ad5.PGT121 afforded more rapid, robust, and durable antiviral efficacy than AAV1.PGT121 and purified PGT121 IgG in HIV-1-infected humanized mice., Version of Record

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results